Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has ...

Pfizer (NYSE:PFE) recently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in ...

Pfizer (PFE) stock slips as the company halts development of danuglipron for weight loss due to liver injury concerns. Read ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Here is why it could be a smart buy now. Not every stock needs to be a millionaire-maker. Sometimes, slow and steady can win ...

Pfizer Inc. (NYSE:PFE – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the company, Marketbeat reports.

According to TipRanks, Meacham is a 3-star analyst with an average return of 0.5% and a 48.33% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, ...

Pfizer discontinues development of weight-loss pill. Investors now expect it to acquire VKTX to expand in the anti-obesity ...